Showing results (291-300 of 319) with videos related to

Sort By:
Pageof 32
Cancer|June 25, 2025
Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvementElizabeth L Godfrey, Forest Mahoney, Varun V Bansal, et al.
JCI Insight|April 20, 2017
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patientsVivek Subbiah, Muhammad Rizwan Khawaja, David S Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|February 14, 2025
Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 studyAlberto Sobrero, Arvind Dasari, Jeneth Aquino, et al.
Annals of Surgical Oncology|June 25, 2025
Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 2: Appendiceal Tumors with Peritoneal InvolvementElizabeth L Godfrey, Forest Mahoney, Varun V Bansal, et al.
Journal for Immunotherapy of Cancer|August 25, 2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)Benny Johnson, Cara L Haymaker, Edwin R Parra, et al.
The Oncologist|March 19, 2022
Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single InstitutionEmma B Holliday, Van K Morris, Benny Johnson, et al.
Cancer Discovery|December 20, 2011
A novel platform for detection of CK+ and CK- CTCsChad V Pecot, Farideh Z Bischoff, Julie Ann Mayer, et al.
Cancer|June 25, 2025
Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvementElizabeth L Godfrey, Forest Mahoney, Varun V Bansal, et al.
Investigational New Drugs|March 3, 2023
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumorsAntonio Jimeno, Joaquina Baranda, Wade T Iams, et al.
Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.
Pageof 32